对生长中的肿瘤产生的自发性新抗原特异性 CD4(+) T 细胞反应在功能和表型上具有多样性

CD4 + T cells play a critical role in the positive and negative regulation of cellular immunity through the many functional subsets they comprise. The progressive growth of immunogenic tumors which nonetheless generate mutation-specific T cells suggests that effective immune control may be avoided or suppressed at the level of the neoantigen-specific CD4 + T-cell response. Despite their importance, little is known about the ontogeny, architecture, and development of the CD4 + NeoAg-specific repertoire induced by progressively growing tumor.

We used a tetramer specific for a validated neoantigen, CTLC H129>Q /I-A k , to characterize the ontogeny of natural CD4 + T-cell responses to an aggressive and poorly immunogenic major histocompatibility complex class II-deficient tumor, squamous cell carcinoma VII (SCC VII), during progressive growth or following therapeutic peptide vaccination using a combination of flow cytometry, single-cell genomics, and T-cell receptor (TCR) gene engineering.

We find that the natural CD4 + T-cell response to a growing tumor is phenotypically and functionally diverse, with distinct subsets including type 1 helper, T follicular helper-like, and regulatory T cell (Treg) lineages appearing as early as 9 days after tumor implantation. Therapeutic vaccination using the CLTC H129>Q peptide in adjuvant plus α-programmed cell death protein-1 reduces the frequency of CLTC H129>Q -specific Treg in both tumor and tumor-draining lymph node. Single-cell transcriptomic analysis of CLTC-specific CD4 + T cells recapitulated and extended the diversity of the response, with TCRs of varying affinity found within each functional subset. The TCR affinity differences did not strictly correlate with function, however, as even the lowest affinity TCRs isolated from Treg can mediate therapeutic efficacy against established tumors in the setting of adoptive cellular therapy (ACT).

These findings offer unprecedented insight into the functional diversity of a natural neoantigen-specific CD4 + T-cell response and show how immunotherapeutic intervention influences the phenotype, magnitude, and efficacy of the antitumor immune response. This information could lead to new approaches to immune monitoring in the clinical setting of checkpoint blockade immunotherapy and cancer vaccines. Furthermore, we show that Treg can be a potent source of TCRs that can mediate therapeutic benefit in the setting of ACT.